Current guidelines1,2 recommend antipsychotic medication (or “neuroleptics”) for adults diagnosed with “schizophrenia” and other diagnoses indicative of psychosis. Antipsychotic drugs are also increasingly used for other mental health problems and with adolescents, older people and prisoners. Recent studies and reviews, however, suggest that claims about their efficacy may have been overstated.3–8 A recent meta-analysis of 167 RCTs found that 23% in the drug group and 14% on placebos had a “good response.” 9 Adverse effects can be severe. They include tardive dyskinesia, cardiovascular effects (eg, cardiac arrhythmia, lengthening of Q-T interval, sudden cardiac death), metabolic effects (eg, glucose intolerance, diabetes, high cholesterol levels, obesity), sexual dysfunction, sedation, dizziness, akathisia, dry mouth, reduced brain volume, and shortened life span.3,10–14
Thus far, surveys or interviews about the first-hand experience of people taking these drugs have not played a significant role in evaluating these drugs. Some of these qualitative studies confirm a plethora of commonly experienced and disruptive biological adverse effects (eg, neurological, metabolic, cardiovascular), but have also identified a range of negative effects and functional impairments in the less well researched psychological and interpersonal domains.15–20 A few studies have focused on the difficulties of withdrawing.21–24 Others have addressed the prescribing and decision-making processes.25–27 A recent study of 20 antipsychotic users26 found opinions divided between “willing acceptance” to taking antipsycotics, “resigned acceptance,” and “nonacceptance,” but “they commonly experienced their prescribing psychiatrist as not sufficiently acknowledging the negative impacts of medication on life quality and physical health concerns.” Even 69 British people who mostly found antipsychotics helpful did not feel involved in treatment decisions and had not been warned about side effects or offered alternative treatments.28
The largest survey to date, of 832 antipsychotic users from 30 countries, found that 64% reported 10 or more adverse effects, including sedation (92%) and suicidality (58%). Equal proportions found the drugs “helpful” (41%) and “unhelpful” (43%). The current article reports the qualitative data, from the same survey, to reveal what it is that people find helpful and unhelpful about antipsychotics.29
The study was approved, in Melbourne, by Swinburne University of Technology’s Human Research Ethics Committee.
The Experiences of Antidepressant and Antipsychotic Medication Survey,29,30 an online questionnaire, has quantitative and open questions about: prescribing experience, positive and negative effects of medications, causal beliefs, alternative treatments, and withdrawal. This article reports responses to 2 open questions: “Overall in my life antipsychotic medications have been _____?” and, at the end of the survey, “Is there anything else you would like to say, or emphasise, about your experiences with antipsychotic drugs?”
Of the 2346 people who responded 668 were recruited by an Australian research company, and 1678 people via advertisements on social media and snowball sampling30; 963 met the following criteria: “I have been taking or have previously taken antipsychotic medication continuously for at least one month”; “I am aged 18 or older”; and “I am not currently compulsorily detained in a psychiatric hospital.” 29 Fifty-one matched the Internet Protocol address of another response, indicating the same device was used; 25 of these were excluded because of identical demographics or similar responses. Of the remaining 938, 27 responded to “What is the name of your current or most recent antipsychotic medication?” with something other than antipsychotics. Of the remaining 911, 261 did not respond to either question, leaving 650 to be included in the analysis.
Responses to the 2 questions were combined for each participant. A Likert scale, from 1—“extremely positive” to 7–“extremely negative” (table 1), provided an Overall Antipsychotic Rating (OAR) score. Reliability was assessed by one of the researchers independently scoring 20 random items, blind to the scores of the main scorer. Inter-rater reliability was 95% (19/20). This translates to a kappa, which allows for expected agreement by chance, of 0.94. Kappa scores above 0.75 are considered “excellent.” 31 The relationship of OAR scores with age and treatment duration was analyzed with Spearman rank correlation coefficients (rho), and with gender using a 2-tailed t-test.
|Scale Point||Criteria||Examples||n (%)|
|1||Extremely negative: Superlatives (“very” or “extremely”) OR strong or extremely negative descriptor||“torturous,” “disastrous,” “poison,” “extreme pain”||227 (34.9%)|
|2||Negative: All negative but without extremes||“frustrating,” “unhelpful,” “ineffective”||148 (22.8%)|
|3||Mixed, mostly negative: More negative than positive issues identified||“felt disconnected, gained weight and felt like an emotional zombie, but they did help me sleep”||60 (9.2%)|
|4||Equally balanced: Equal number of positive and negative issues OR one extreme that balances out several minor issues||“beneficial but problematic,” “mixed blessing” “helpful short-term, unhelpful long-term” “a saviour and a curse both”||71 (10.9%)|
|5||Mixed, mostly positive: More positive than negative issues identified||“reduced hallucinations, delusions and reconnected me with people but experienced weight gain”||51 (7.8%)|
|6||Positive: All positive but without extremes||“helpful,” “effective”||56 (8.6%)|
|7||Extremely positive: Superlatives (“very” or “extremely”) OR strong or extremely positive descriptor||“lifesaving,” “wonderful,” “very helpful”||37 (5.7%)|
Thematic analysis32 was used to identify themes. Units of analysis (participants’ written answers, or parts thereof) were first classified as positive, negative, or mixed and then into themes and subthemes, by one of the researchers. The other researcher independently assigned 44 units of analysis to the 22 subthemes generated by the main coder, blind to their original coding (one each of the 22 subthemes and an additional random 22). Inter-rater reliability was 86.4% (38/44), which is a kappa of 0.857. The 6 discrepancies included overlapping subthemes. For example, “withdrawal” and “difficult to get off them” were initially separate categories, but it was agreed they were too similar and were combined into one category.
The majority of the sample (71.6%) were women. Ages ranged from 18 to 76, with an average of 43.0 (SD 13.07). Participants were from 29 countries, but the majority (72.2%) were from the United States (25.1%), Australia (24.5%), or the United Kingdom (22.6%). Other countries contributing more than 1% were: New Zealand (4.5%), Canada (3.8%), the Netherlands (3.1%), Denmark (2.5%), Ireland (2.5%), Germany (2.2%), Norway (1.8%), South Africa (1.4%), and Switzerland 1.2%. The following countries contributed from 1 to 5 participants: Austria, Belgium, Croatia, Estonia, Finland, France, Greece, India, Israel, Italy, Lithuania, Poland, Portugal, Romania, Spain, Sweden, and Ukraine. The most frequently reported ethnicities (self-definition) were “white”/“Caucasian” 319 (49.1%), “Australian” 73 (11.2%), and “European” 36 (6.0%). A quarter (24.6%) had taken antipsychotics for 1–12 months, 18.1% for 1–3 years, and 57.2% for more than 3 years.
Of the 650 participants, 579 provided their “primary diagnosis.” DSM-V groupings cited by 5 or more participants were represented as follows: “Schizophrenia Spectrum and Other Psychotic Disorders”–200 (34.5%); “Bipolar and Related Disorders”—140 (21.5%); “Depressive Disorders”—137 (21.1%); “Personality Disorders”—42 (7.3%); “Trauma and Stressor-Related Disorders”—19 (3.3%); “Obsessive-Compulsive and Related Disorders”—8 (1.4%); “Anxiety Disorders”—8 (1.4%); “Dissociative Disorders”—6 (1.0%); and “Neurodevelopmental Disorders”—5 (0.9%). Secondary diagnoses included 49 in the schizophrenia spectrum, bringing the total (primary or secondary) for that grouping to 249 (43.0%).
In the survey’s quantitative section,29 roughly equal numbers of the 650 in the current sample reported that the drugs were “helpful” (40.1%) and “unhelpful” (44.5). More found that the drugs had “reduced the problems for which they were prescribed” (55.4%) than thought they had been made “worse” (27.6%). More reported that their “Quality of Life” had been made worse (56.0%) than thought it had been “improved” (34.9%).
Table 1 shows that two-thirds (66.9%) of the participants were categorized as more negative than positive, with 34.9% being “extremely negative.” Nearly a quarter of participants’ responses (22.1%) were categorized as more positive than negative, with 5.7% “extremely positive.” Mixed responses comprised over a quarter of participants’ responses (27.9%), with 10.9% categorized as equally balanced.
The mean score on the OAR scale (1–7) was 2.83 (SD 1.93), well to the negative side of the midpoint of 4. OAR was not related to gender or duration of treatment. Older age was related to lower, more negative, scores (rho = 0.13, P = .001). The 249 respondents with a primary or secondary diagnosis in the schizophrenic spectrum had a significantly more negative mean OAR score (2.53) than those without such a diagnosis (2.99) (t = 2.90, df = 577, P = .004). Nevertheless, the majority of both groups were categorized as more negative than positive (schizophrenia—72.7%; other—63.3%).
Most of the 982 individual statements (units of analysis) were clearly either positive (180, 18.3%) or negative (749, 76.3%). There were 53 instances (5.4%) where the positive and negative components of a mixed statement could not be separated into smaller units of assessment without losing meaning. These were most commonly statements about short- vs long-term experiences. Positive quotes were categorized into 3 themes (see table 2 for examples from each of the 3 themes). Mixed quotes were categorized into 2 themes (table 3). Negative quotes were categorized into 5 themes, 2 of which were further divided into subthemes (tables 4 and 5).
|Themes||Age, Gender, Country|
|Unspecified positive experiences (n = 152)|
|Helpful||32, M, India|
|It’s helpful. I don’t want to stop taking my medication||48, M, The Netherlands|
|Having the medication makes it possible to thrive instead of just surviving on a day to day basis||33, F, United States|
|It was the right choice of treatment. I benefitted greatly from using it||37, F, South Africa|
|I consider being prescribed antipsychotic medication to have allowed me to start living a life and have a future that I had never even imagined as a teenager as I didn’t think I would be alive||30, F, New Zealand|
|I don’t know how I would survive without them||31, F, United States|
|I cannot over-estimate their helpfulness. My life is hell without them||58, F, United Kingdom|
|Sleep (n = 14)|
|If forgotten to take sleep is impossible||35, F, United Kingdom|
|They are not “antipsychotic” they just helped me sleep||53, M, Canada|
|Symptom reduction (n = 14)|
|They stopped the voices, and bought me back to reality||39, F, Ireland|
|They have taken away delusions and paranoia||40, F, Ireland|
|I had an alternative to suicide/self-harm and stopping my distressing thoughts and extreme emotions||30, F, New Zealand|
|Themes||Age, Gender, Country|
|Unspecified mixed experiences (n = 25)|
|Necessary, but not without heavy price||33, F, United States|
|Beneficial but problematic||45, F, United Kingdom|
|Is a necessary evil||31, M, United Kingdom|
|Short-term good, long-term bad (n = 28)|
|Useful in the short term, a curse in long term use||49, M, New Zealand|
|Maybe helpful for a short time, but likely not worth it in the end they clouded my perceptions and sense of self very badly||34, M, ?|
|Good short (very short term) but hurting my feeling competent person if insisted to use life-long||61, F, Lithuania|
|There are times they are necessary in certain doses and temporarily, but it is not the solution to the problem long term||39, F, Spain|
|Helpful until they were harmful. At this point it’s hard to know what’s caused by the drug or helped by it!||24, F, United States|
|Themes||Age, Gender, Country|
|Adverse Effects (n = 316)|
|1. Unspecified Side Effects (n = 55)||The side effects were bad enough that I considered stopping the treatment||23, F, United Kingdom|
|Awful side effects I never had before being put forced to take injections depot||66, F, United Kingdom|
|I don’t feel like the benefits of the antipsychotic have been worth the negative side effects for me||28, F, New Zealand|
|Virtually every antipsychotic I tried gave me very serious side effects||31, F, United States|
|2 Physical (n = 117)|
|(2a) Weight gain (n = 58)||My body is still scarred with stretch marks from the uncontrollable weight gain||24, M, United States|
|The fight against weight gain is a nightmare||73, F, United Kingdom|
|I think they made me gain like 10 kg and that bummed me out as a teens/20s girl||26, F, United Kingdom|
|I put on 27 kg and developed diabetes||67, F, Australia|
|(2b) Sedation (n = 19)||I refuse to call these medications antipsychotics. They are major tranquilizers||40, M, Australia|
|Severe sedation made it impossible to continue||46, F, Australia|
|(2c) Unspecified (n = 16)||Very damaging to my mental and physical health||59, F, United States|
|It contributed to the deterioration in my physical health||50, F, Australia|
|(2d) Akathisia (n = 15)||I developed severe akathisia within a week of the first dose of Depixol. It lasted over 3 months and ended in a hospital admission||26, F, United Kingdom|
|The inner restlessness was probably one of the worst side effects I have ever experienced. Developed muscle spasms, jerking limbs, twitching, inner agitation, restless legs, and could no longer function||34, F, Australia|
|Created an at times unbearable internal restlessness that drove me to suicidal thoughts||51, F, New Zealand|
|(2e) Tardive Dyskinesia (n = 9)||Due to the rather large doses I have long-term TD and seizures||35, M, Australia|
|The big movements are ugly; the small ones make you look stupid; your mouth is never comfortable again; there are always sores from teeth clamping down; and tongue has no place to rest and feels it does not belong in your mouth. I wish they had killed me instead||55, F, United Kingdom|
|3 Psychological (n = 80)|
|(3a) Emotional numbing (n = 42)||I was very emotionally numb when on antipsychotics||20, F, United States|
|If the point of antipsychotics is to make you an emotional and spiritual zombie, they succeeded||27 F, United States|
|They dumb me down & numb me up, I have no happiness or joy||44, M, Ireland|
|They made me feel less than human, dead inside||39, F, United Kingdom|
|Terrible side effects. Zombified and unable to collect thoughts||58, F, United Kingdom|
|It also shut down the good/happy things and the lively energy. … just emptied the whole world from meaning and shut me down completely||30, F, Israel|
|(3b) Cognitive dysfunction (n = 28)||They took away the one thing I had previously been able to rely on: my mind, and rendered it useless||51, F, New Zealand|
|I was frightened about my loss of mental acuity||63, F, United States|
|These are difficult drugs to take. Having cotton wool for a brain was not easy||27, F, United Kingdom|
|(3c) Caused or exacerbated psychosis (n = 10)||20 mg of olanzapine gave me the worst hallucinations I have ever experienced||48, F, New Zealand|
|They caused psychosis, something I hadn’t experienced before||70, F, Norway|
|It did not make the voices go away; it increased the amount of voices and how often I heard them||50, F, Australia|
|4. Long Term (n = 31)||It has now been over 4 years and I am still suffering severe side effects||45, M, New Zealand|
|I have long-term physical issues as a result of their use, including tremors and an autoimmune response associated with taking long-term pharmaceuticals||50, F, United States|
|2+ years after stopping still have sleep issues as withdrawal symptoms||72, F, Australia|
|I believe my health has been permanently damaged and my life shortened by unnecessary psychiatric drugging||54, F, Canada|
|5. Relationships (n = 17)||Antipsychotics were life shattering. Imagine not being able to connect with partners anymore||28 F Canada|
|I lost 10 years of my life. I withdrew from my sons, my siblings, and my friends||70, F, United States|
|Loss of concentration meant I couldn’t keep up friendships etc.||74, F, Australia|
|I could not relate to my partner and 4 children||58, F, Australia|
|6. Suicidality (n = 16)||Worst experience of my life. I had such severe akathisia (a side effect from antipsychotics) I felt like killing myself||41, F, United Kingdom|
|My first and only suicide attempt was because of the restlessness of akathisia. No one would believe how much pain I was in||26, F, United Kingdom|
|When I am not on psychiatric medication I am not suicidal. I want professionals and medication users to acknowledge suicidality can happen||27, F, United States|
|The flattening of my emotional, sexual, and social state was unbearable. This lack of pleasure in my life drove me to suicidal ideation. No attempt was made, but it got to a plan||55, F, United Kingdom|
|Antipsychotics made me suicidal, and I tried to kill myself when under a Community Treatment Order. I’ve never been suicidal when not on antipsychotics||42, F,?|
|Themes||Age, Gender, Country|
|Unspecified Negative Experiences (n = 191)|
|Taking them was a very frightening experience. I would never want to repeat it||43, F, United States|
|A disaster. Antipsychotics took away the best years of my life||42, F, United States|
|Basically makes life unliveable, pointless, and increases suffering||23, M, Estonia|
|These medications are disabling. They are dehumanizing||40, M, Australia|
|Antipsychotics are poisons||48, M, Canada|
|Interactions With Prescriber (n = 169)|
|1. Lack of Support (n = 64)||My psychiatrist would not support any sort of medication reduction so I did it myself by going cold turkey— not something I would recommend!||45, F, United Kingdom|
|My suffering continues and I have NO SUPPORT from the medical profession||22, M, New Zealand|
|I am now being refused support because I am deemed as “non-compliant”||26, F, United Kingdom|
|Why did no one listen to me?||46, F, United Kingdom|
|… through the hell of withdrawal with zero support from the medical community||34, F, New Zealand|
|Lack of professional and personal support||58, F, Norway|
|e2. Lack of Informed Consent (n = 56)||If I had known about the risks of these medications, I would have never have taken them||30, M, United Kingdom|
|I don’t think the potential side effects are explained well enough or the impact they have on your life taken seriously enough||36, F, United Kingdom|
|I think, given the significant side effects, it is important to clearly communicate to the patient the real risks involved, the purpose of it, what the plan is for its use (short or long term). This didn’t happen for me||42, F, United States|
|I was not warned about permanent/semi-permanent effects of antipsychotics which I got||22, F, Ukraine|
|I was told NOTHING about them||59, F, United Kingdom|
|The info from the doctors is very slanted and does not fully warn you of long-term effects||50, F, New Zealand|
|I think I would have gained better results earlier, with more information from the beginning||46, F, Norway|
|3. Lack of Alternative Approaches Offered (n = 21)||Being presented with medications as the only possibility to feel relief from overwhelming distress turns the decision into: “feel this afraid and miserable forever or take these medications”||30, F, Canada|
|Why wasn’t I told about alternative mental health help/methods?||36, F, United States|
|Other avenues should definitely be explored before resorting to prescribing antipsychotics. I literally just met this doctor for the first time, had a half an hour-long conversation and BOOM||25, F, United Kingdom|
|I wish there was alternative treatment available like psychotherapy when I needed help||28, M, India|
|4. Lack of Information Regarding Withdrawal Effects (n = 17)||If I had known the seriousness of withdrawing from my medication, I would have not relapsed||35, F, United Kingdom|
|They never talk about withdrawal or secondary withdrawals||41, F, United States|
|Most doctors do not have a clue. They turn their backs on suffering patients, denying the existence of withdrawal damage||M, 22, New Zealand|
|5. Misdiagnosis (n = 11).||I had never expected I would be prescribed antipsychotics given my symptoms and diagnosis are entirely consistent with anxiety. I have zero psychotic symptoms||31 F Australia|
|“Akathisia” was misdiagnosed as “agitated depression” and “converted from depression to bipolar,” requiring MORE meds||46 M United Kingdom|
|Withdrawal/Difficult to Get Off (n = 62)|
|I wish I never started. Now I am slowly quitting, but withdrawal is terrible||38, F, The Netherlands|
|It was not worth it and it took a full darned year to finish withdrawals and even begin to feel normal||65, F, United States|
|I suffered hallucinations and headaches during withdrawal even from stopping a low dosage||32 F United Kingdom|
|The withdrawals process has ruined 4 years of my life so far and counting||52 M United States|
|The withdrawal process was horrible and caused very distressing physical, mental, and emotional changes||35, F, United States|
|The withdrawal process was almost worse than the illness itself||41, F, United States|
|Withdrawal from the antipsychotic was torturous and took a very long time. I would never choose to take them again, ever||34 F Australia|
|Withdrawal symptoms were always blamed on relapse of my “disease”||34, F, United States|
|Ineffective (n = 11)|
|They do not work||58, F, United Kingdom|
This is the largest survey directly addressing people’s experiences with antipsychotics. In this sample, of 650 people from 29 countries, open questions led to negative experiences far outweighing positive ones, with many participants reporting mixed accounts. This suggests that studies focusing on symptom reduction, including RCTs, may be missing the broader impact of drugs on people’s lives.
Nearly a quarter of participants’ responses (22.1%) were categorized as more positive than negative on the OAR scale (scale points 5–7); 5.7% were scored as “extremely positive,” with several people characterizing the drugs as life-changing or even life-saving. In the thematic analysis, 18.3% of the units of analysis were positive with a further 5.4% mixed. These findings are similar to the meta-analysis of 167 double-blind randomized controlled trials which found that an average of 23% had a “good” response.9 In the current study, relatively few people who experienced the drugs positively were able to articulate specifically why or how. Only 14 people said that the drugs reduced psychotic symptoms. Of the 180 units coded as positive, 153 (85.0%) were “unspecified” but this was the case for only 25.5% of the negative units (191/749).
The broad range, and high frequencies of the adverse effects reported, such as emotional numbing/sedation, weight gain, and cognitive dysfunction, are broadly consistent with previous studies, both qualitative15–18,33 and quantitative.3,4,11 Further research and clinical attention are urgently needed to address the incidence and severity of withdrawal effects and suicidality. In the current sample, these were reported by 65% and 58%, respectively when asked directly in another section of the survey.29 The recent schizophrenia guidelines published by the German Association for Psychiatry, Psychotherapy and Psychosomatics34 is, to our knowledge, the first national guidelines to properly address withdrawal from antipsychotics.
Another area in need of greater focus is the long-term adverse effects, which some participants reported continued even after coming off the drugs.
Another major finding emanating from use of open questions rather than closed questions on topics chosen by researchers is that the negative opinions were not just based on the adverse effects of the drugs prescribed, but also, in large numbers, based on dissatisfaction with interactions with the prescriber, or with mental health services in general. Despite neither of our questions asking about the topic, 169 comments were about the lack of information or support. Failure to fully inform people of adverse effects breaches the fundamental ethical principle of informed consent. Yet, in the quantitative section of the survey, only 30.2% replied “yes” to “Did the doctor inform you of any possible side effects?”, identical to the larger sample29 (which included those who did not respond to the 2 questions analyzed here). This is comparable to the extent to which people are told about the adverse effects of antidepressants.30,35–37 Other qualitative studies of users of antipsychotics have highlighted the importance of relationships with prescribers.25–28,38
The 21 participants who reported that they were not given an alternative to antipsychotic medication align with a recent study that found practitioners were often reluctant to consider reduction or to propose alternative approaches to antipsychotics.39 This is inconsistent with the recommendation that decision-making should be shared.2
The finding that older age is correlated with more negative OAR scores is matched by quantitative data from the same survey,29 and by other studies finding particularly high rates of adverse effects in older people.40–42 This is of particular concern given the increasing inappropriate, “off-label” use of antipsychotics with older people, especially those in care.42,43
The findings from this study regarding short-term benefit/long-term negatives, and functional impairment, are consistent with previous studies demonstrating greater long-term functional impairment in those staying on antipsychotics for several years.3,5,6,12,17,44,45
Reviews show that alternatives to antipsychotic medications may have equally good, or better, outcomes.3,5,46,47 Examples of moves toward alternatives are the “Open Dialogue” approach,48 the Hearing Voices Network,49 and the government-mandated creation of drug-free treatment options in Norway.50
Many of the problems that need addressing here were captured by a 40-year-old woman in the United Kingdom who answered the first question with “Necessary evil” and added, in response to the second question, “Should have been told about side effects, shouldn’t have been brushed off when I raised concerns about side effects, shouldn’t have been left to take them long term, should have been able to discuss other options.”
A limitation of this study is that it uses a convenience sample, not a randomly selected one. It is possible that people who were dissatisfied with their antipsychotics were more likely to participate. More than half, however, had reported that the drugs had to some extent reduced the problems for which they had been prescribed, a figure far higher than most drug trials report.9 Even if the sample were biased, toward either those with positive or negative experiences, the study still provides important insights into what the largest sample to date find helpful and unhelpful about taking antipsychotic drugs.
The fact that it was an online survey may mean that the economically disadvantaged may be underrepresented because of lack of internet access. People from “developing” countries and ethnic minorities were certainly underrepresented.
Another limitation is that the data were self-reported. Some of the adverse effects may not have been related to the antipsychotics. It is also possible that some of the positive outcomes may have resulted from life changes, spontaneous remission, or placebo effects.
Asking open-ended questions about first-hand experiences allows deeper insight than asking participants to respond to specific questions predetermined by researchers. The most recent and thorough review, of 35 qualitative studies of people’s experiences of taking antipsychotics (or “neuroleptics”), suggests that “The rich nature of qualitative data means these studies can highlight the complex alterations to conscious experience, mental functions and behavior that neuroleptics produce, arguably more successfully than quantitative approaches (e.g. use of side effect scales)’. The reviewers found that ‘Users of neuroleptics consistently described a consistent experience, characterised by sedation, cognitive impairment, emotional blunting and reduced motivation, which was associated with a variety of physical effects, including neurological effects, weight gain and sexual dysfunction”.51
The 650 people who gave their time to share their experiences, positive and painful, seem to be telling us that the important things for clinicians (and researchers) to pay attention to include: establishing a collaborative, respectful relationship with potential users of antipsychotics, which requires the provision of full information about all possible adverse effects, including sedation, suicidality and withdrawal effects, and about alternative treatment pathways; and responding respectfully and therapeutically when patients voice the sorts of concerns raised in this study and the 35 previous qualitative studies.51
The authors have declared that there are no conflicts of interest in relation to the subject of this study.
1. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 2010.
2. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults. Quality Standard. London: NICE; 2015.
3. Hutton P, Weinmann S, Bola J, Read J. Antipsychotic drugs. In: Read J, Dillon J, eds. Models of Madness: Psychological, Social and Biological Approaches to Psychosis. London: Routledge; 2013:105–124.
4. Bola J, Kao D, Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev. 2011;CD006374.
5. Bola J, Lehtinen K, Cullberg J, Ciompi L. Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first episode psychosis. Psychosis. 2009;1:4–18.
6. Harrow M, Jobe TH, Faull RN, Yang J. A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Res. 2017;256:267–274.
7. Jung E, Wiesjahn M, Wendt H, Bock T, Rief W, Lincoln TM. Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol Med. 2016;46(10):2179–2188.
8. Moilanen J, Haapea M, Miettunen J, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication: a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Europ Psychiatry. 2013;28:53–58.
9. Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942.
10. Miller D, Caroff S, Davis S, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279–288.
11. Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39(1):29–39.
12. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128–137.
13. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113(1):1–11.
14. Weinmann S, Aderhold V. Antipsychotic medication, mortality and neurodegeneration. Psychosis. 2010;2:250–269.
15. Day JC, Bentall RP, Warner S. Schizophrenic patients’ experiences of neuroleptic medication: a Q-methodological investigation. Acta Psychiatr Scand. 1996;93(5):397–402.
16. Day JC, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998;97(1):93–97.
17. Bjornestad J, Lavik K, Davidson L, Hjeltnes A, Moltu C, Veseth M. Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies. [published online ahead of print March 12, 2019]. J Ment Health. doi: 10.1080/09638237.2019.1581352.
18. Murphy AL, Gardner DM, Kisely S, Cooke C, Kutcher SP, Hughes J. A qualitative study of antipsychotic medication experiences of youth. J Can Acad Child Adolesc Psychiatry. 2015;24(1):61–69.
19. Morrison P, Meehan T, Stomski NJ. Living with antipsychotic medication side-effects: the experience of Australian mental health consumers. Int J Ment Health Nurs. 2015;24(3):253–261.
20. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120(2): 102–111.
21. Geyt G, Awenat Y, Tai S, Haddock G. Personal accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res. 2016;26:1–16.
22. Larsen-Barr M, Seymour F, Read J, Gibson K. Attempting to stop antipsychotic medication: success, supports, and efforts to cope. Soc Psychiatry Psychiatr Epidemiol. 2018;53(7):745–756.
23. Larsen-Barr M, Seymour F, Read J, Gibson K. Attempting to discontinue antipsychotic medication: withdrawal methods, relapse and success. Psychiatry Res. 2018;270:365–374.
24. Salomon C, Hamilton B. ‘All roads lead to medication?’ Qualitative responses from an Australian first-person survey of antipsychotic discontinuation. Psychiatrc Rehabil J. 2013;36:160–165.
25. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717–724.
26. Morant N, Azam K, Johnson S, Moncrieff J. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health. 2018;27(4):322–328.
27. Morant N, Kaminskiy E, Ramon S. Shared decision making for psychiatric medication management: beyond the micro-social. Health Expect. 2016;19(5):1002–1014.
28. Gray R, Rofail D, Allen J, Newey T. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication. J Adv Nurs. 2005;52(1): 31–37.
29. Read J, Williams J. Positive and negative effects of antipsychotic medication: an international online survey of 832 recipients. Curr Drug Saf. 2019;14(3):173–181.
30. Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Curr Drug Saf. 2018;13(3):176–186.
31. Fleiss J. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1981.
32. Braun V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
33. Wykes T, Evans J, Paton C, et al. What side effects are problematic for patients prescribed antipsychotic medication? the maudsley side effects (MSE) measure for antipsychotic medication. Psychol Med. 2017;47(13):2369–2378.
34. DGPPN (ed.). S3 Guideline for Schizophrenia. Abbreviated version (English), 2019, Version 1.0, last updated on December 15, 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html
35. Byng R, Bury C, Weaver L. Patients’ experiences of consultations for depression and predictors of adherence to antidepressants. Primary Care Comm Psychiatry. 2007;12:109–115.
36. Read J, Cartwright C, Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Ment Health Nurs. 2018;27(6):1805–1815.
37. Read J, Gee A, Diggle J, Butler H. The interpersonal adverse effects reported by 1008 users of antidepressants; and the incremental impact of polypharmacy. Psychiatry Res. 2017;256:423–427.
38. Stevenson FA, Barry CA, Britten N, Barber N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med. 2000;50(6): 829–840.
39. Cooper RE, Hanratty É, Morant N, Moncrieff J. Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLoS One. 2019;14(6): e0218711.
40. Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242–248.
41. Jeste DV, Maglione JE. Treating older adults with schizophrenia: challenges and opportunities. Schizophr Bull. 2013;39(5):966–968.
42. Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76(10):1346–1353.
43. Alexander G, Gallagher S, Mascola A, Moloney R, Stafford R. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Phamacoepidemiol Drug Saf. 2011;20:177–184.
44. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis. 2007;195(5):406–414.
45. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–920.
46. Cooper R, Laxhman N, Crellin N, Moncrieff J, Priebe S. Psychosocial interventions for people with psychosis or schizophrenia on minimal or no antipsychotic medication: a systematic review. Schizophr Res. 2019;30:182–183.
47. Calton T, Ferriter M, Huband N, Spandler H. A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull. 2008;34(1):181–192.
48. Aaltonen J, Seikkula J, Lehtinen K. The comprehensive open-dialogue approach in Western Lapland. Psychosis. 2011;3:179–191.
49. Longden E, Read J, Dillon J. Assessing the impact and effectiveness of hearing voices network self-help groups. Community Ment Health J. 2018;54(2):184–188.
50. Heskestad S, Kalhovde A, Jakobsen E, et al. Drug-free psychiatric treatment – what do the patients think? Tidsskr Nor Laegeforen. 2019;139(14). doi: 10.4045/tidsskr.18.0912.
51. Thompson J, Stansfield J, Cooper R, Morant N, Crellion N, Moncrieff J. Experiences of taking neuroleptic medication and impacts on symptms, sense of self and agency: a systematic review and thematic synthesis of qualitative data. Soc Psychiatry Psychiatr Epidmiol. 2020. doi: 10.1007/s00127-019-01819-2.